arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Inhibrx Biosciences, Inc.

INBX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$94.68
▼ -3.6% Today
as of Oct 23, 10:03 ET
Last 30 days -14.29% Sep 14 → Oct 23
$83.12 $90.88 $98.65 $106.42 $114.18 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$95.65
High
$100.20
Low
$94.04
Volume
$249,508
Avg Vol
$342,035
Mkt Cap
$1.4B
P/E (TTM)
—
Beta
—
52w High
$155.29
52w Low
$28.16
Div Yield
—
Shares Out
$15M

Recent Press Releases & News last 60 days · 13 items

Oct 14 · 14:14 Simply Wall St.
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?
Oct 13 · 20:00 PR PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 2 · 12:00 MarketBeat
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
▸ Show all 13 press releases & news Free account →

INBX earnings at a glance

The options market is pricing a move of about ±12.2% after the report, a range of roughly $83.09 to $106.27 from today's $94.68. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±2.7% on average; after the most recent report on May 14, 2026 it moved -1.5%. That means options currently expect more movement than INBX has typically delivered. INBX beat the consensus EPS estimate in 2 of its last 3 reported quarters. Implied volatility is currently 104%. The share price of $94.68 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$28
$155
52% of range
Avg surprise (last 3)
+12.0%
Avg reaction (last 2)
-2.7%
0% positive
Latest IV / EM
104%
EM ±12.2% · $95 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-5.77$27.04$59.86$92.67$125.48 Actual $-4.31Actual $-4.39Actual $-5.77Actual $125.48Actual $-2.84Actual $-2.80Est $-2.55Actual $-1.85Est $-2.92Actual $-2.28Actual $-2.15Est $-2.37Actual $-2.34 JunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-44M$-33M$-21M$-10M$1M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-2.34 — — — — financials
Thu May 14, 2026Mar/2026 $-2.15 $-2.37 +9.3% +23.2% -1.5% earnings
Fri Nov 14, 2025Sep/2025 $-2.28 — — — — earnings
Wed Aug 13, 2025Jun/2025 $-1.85 $-2.92 +36.6% — — earnings
Wed May 14, 2025Mar/2025 $-2.80 $-2.55 -9.8% — -3.9% earnings
Mon Sep 30, 2024Sep 2024 $-2.84 — — — — financials
Sun Jun 30, 2024Jun 2024 $125.48 — — — — financials
Sun Mar 31, 2024Mar 2024 $-5.77 — — — — financials
Sat Sep 30, 2023Sep 2023 $-4.39 — — — — financials
Fri Jun 30, 2023Jun 2023 $-4.31 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0——$0$1M$0—$0
Cost of revenue————————
Gross profit————————
Operating income$-32M$-31M—$-34M$-27M$-43M—$-47M
Net income$-37M$-33M—$-35M$-29M$-43M—$-44M
EPS (diluted)$-2.34$-2.15—$-2.28$-1.85$-2.80—$-2.84

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$133M$162M$124M$153M$187M$217M$153M$196M
Inventory————————
Total current assets$142M$171M$133M$161M$194M$223M$160M$207M
Total assets$154M$184M$146M$177M$212M$243M$181M$223M
Long-term debt$176M$175M$101M$100M$99M$99M$0$0
Total liabilities$207M$205M$138M$141M$144M$148M$47M$44M
Total equity$-53M$-21M$8M$37M$69M$94M$134M$178M

Implied volatility — last 90 days

77%127%178%228%279% Jun 07 — IV 118% · EM ±16.3%Jun 08 — IV 99% · EM ±13.1%Jun 09 — IV 95% · EM ±11.8%Jun 10 — IV 121% · EM ±14.3%Jun 11 — IV 124% · EM ±13.7%Jun 12 — IV 147% · EM ±15.1%Jun 15 — IV 155% · EM ±11.2%Jun 16 — IV 195% · EM ±11.5%Jun 17 — IV 280% · EM ±11.7%Jun 19 — IV 78% · EM ±17.2%Jun 22 — IV 83% · EM ±17.4%Jun 23 — IV 85% · EM ±17.4%Jun 24 — IV 79% · EM ±15.9%Jun 25 — IV 82% · EM ±16.1%Jun 26 — IV 77% · EM ±14.8%Jun 29 — IV 80% · EM ±14.1%Jun 30 — IV 80% · EM ±13.8%Jul 01 — IV 92% · EM ±15.4%Jul 02 — IV 78% · EM ±12.5%Jul 03 — IV 95% · EM ±14.8%Jul 06 — IV 90% · EM ±12.4%Jul 07 — IV 104% · EM ±13.7%Jul 08 — IV 87% · EM ±10.9%Jul 09 — IV 92% · EM ±10.9%Jul 10 — IV 109% · EM ±12.1%Jul 13 — IV 114% · EM ±9.5%Jul 14 — IV 137% · EM ±9.9%Jul 15 — IV 142% · EM ±8.4%Jul 16 — IV 270% · EM ±11.3%Jul 20 — IV 97% · EM ±22.9%Jul 21 — IV 96% · EM ±22.3%Jul 22 — IV 92% · EM ±21.1%Jul 23 — IV 93% · EM ±20.9%Jul 24 — IV 91% · EM ±20.2%Jul 27 — IV 84% · EM ±17.6%Jul 28 — IV 105% · EM ±21.4%Jul 29 — IV 94% · EM ±18.9%Jul 30 — IV 96% · EM ±18.9%Jul 31 — IV 93% · EM ±17.7%Aug 03 — IV 102% · EM ±18.1%Aug 04 — IV 101% · EM ±17.4%Aug 05 — IV 100% · EM ±16.7%Aug 06 — IV 104% · EM ±16.9%Aug 07 — IV 97% · EM ±15.2%Aug 10 — IV 128% · EM ±17.7%Aug 11 — IV 127% · EM ±16.8%Aug 12 — IV 129% · EM ±16.2%Aug 13 — IV 118% · EM ±14.0%Aug 14 — IV 120% · EM ±13.2%Aug 17 — IV 133% · EM ±11.1%Aug 18 — IV 137% · EM ±9.9%Aug 19 — IV 144% · EM ±8.5%Aug 20 — IV 173% · EM ±7.2%Aug 24 — IV 117% · EM ±24.5%Aug 25 — IV 123% · EM ±25.2%Aug 26 — IV 122% · EM ±24.4%Aug 27 — IV 122% · EM ±24.0%Aug 28 — IV 135% · EM ±25.8%Aug 31 — IV 140% · EM ±24.8%Sep 01 — IV 139% · EM ±23.9%Sep 02 — IV 144% · EM ±24.0%Sep 03 — IV 147% · EM ±23.7%Sep 04 — IV 146% · EM ±22.8%Sep 07 — IV 170% · EM ±23.5%Sep 08 — IV 105% · EM ±13.9%Sep 09 — IV 97% · EM ±12.1%Sep 10 — IV 100% · EM ±11.8%Sep 11 — IV 96% · EM ±10.6%Sep 14 — IV 124% · EM ±10.4%Sep 15 — IV 152% · EM ±11.0%Sep 16 — IV 192% · EM ±11.3%Sep 17 — IV 162% · EM ±6.8%Sep 21 — IV 82% · EM ±17.1%Sep 22 — IV 85% · EM ±17.4%Sep 23 — IV 84% · EM ±16.8%Sep 24 — IV 84% · EM ±16.4%Sep 25 — IV 87% · EM ±16.6%Sep 28 — IV 88% · EM ±15.6%Sep 29 — IV 83% · EM ±14.4%Sep 30 — IV 93% · EM ±15.6%Oct 01 — IV 88% · EM ±14.3%Oct 02 — IV 82% · EM ±12.8%Oct 06 — IV 90% · EM ±11.9%Oct 07 — IV 80% · EM ±10.0%Oct 08 — IV 104% · EM ±12.2%

Sector peers

TSHA
Taysha Gene Therapies, Inc.
$1.4B $3.81-7.5%
MAZE
Maze Therapeutics, Inc.
$1.5B $31.31-3.9%
IMCR
Immunocore Holdings plc
$1.5B $31.34-2.3%
REPL
Replimune Group, Inc.
$1.2B $11.61-0.9%
IMTX
Immatics N.V.
$1.1B $7.36-4.3%
VOR
Vor Biopharma Inc.
$1.1B $18.43-2.7%

INBX earnings FAQ

What is INBX's expected move for earnings?

Options currently price a move of about ±12.2%, or $11.59 per share either way from $94.68.

How does INBX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.7%, up 0 times and down 2 times.

What is INBX's implied volatility?

INBX's at-the-money implied volatility is about 104% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in